Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q29938787)
Watch
English
NTRK3 Amplification
genetic variant
Amplification
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
Transcript Amplification
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/1281
chromosome
human chromosome 15
genomic assembly
Genome assembly GRCh37
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/1281
genomic start
88418230
genomic assembly
Genome assembly GRCh37
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/1281
genomic end
88799978
genomic assembly
Genome assembly GRCh37
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/1281
biological variant of
NTRK3
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/1281
positive therapeutic predictor for
entrectinib
determination method or standard
CIViC evidence level B
rating
CIViC 1-star trust rating
medical condition treated
cancer
statement disputed by
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/2959
stated in
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
negative therapeutic predictor for
entrectinib
determination method or standard
CIViC evidence level B
rating
CIViC 4-star trust rating
medical condition treated
cancer
1 reference
curator
CIViC database
retrieved
23 September 2020
reference URL
https://civic.genome.wustl.edu/links/evidence/2959
stated in
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Identifiers
CIViC variant ID
1281
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/1281
HGVS nomenclature
no value
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/1281
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
